Changing Era of Diabetes Management – A New Perspective for Dapagliflozin

Manish Maladkar; Ashok Yadav; Shraddha Ghorui

doi:doi:10.11648/j.ijde.20220702.11

| Peer-Reviewed

Changing Era of Diabetes Management – A New Perspective for Dapagliflozin

Manish Maladkar, Ashok Yadav, Shraddha Ghorui

Published in International Journal of Diabetes and Endocrinology (Volume 7, Issue 2)

Received: 21 February 2022 Accepted: 26 March 2022 Published: 9 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Type 2 Diabetes Mellitus (T2DM) treatment has progressed dramatically in recent decades. The recent major expansion of the evidence base for T2DM treatment has resulted in frequent revisions of guidelines for hyperglycemia management. When there were few pharmaceutical options, the management strategy was glucocentric or hyperglycemic control. There has been a significant change from the glucocentric era to a more patient-centered and organ-protection era evident in clinical practice guidelines of diabetes management. In addition, since the diabetes armamentarium has grown and new information has been available, the focus has shifted from hyperglycemia control to a more holistic approach, including cardiovascular and renal benefits of the drugs and safety concerns such as weight gain, hypoglycemia. The introduction of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor class of medications has had a substantial impact on diabetes management. The constant positive findings of multiple Cardiovascular Outcome Trials (CVOTs) with SGLT2 inhibitors prompted a paradigm shift: from hyperglycemia control to a patient-centered approach. As a result, SGLT2 inhibitors have been identified by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as an ideal class for a more patient-centered approach to T2DM treatment, become a driving force in diabetes care. Dapagliflozin, an SGLT2 inhibitor, has recently emerged as a glucose-lowering medication that has been found to not only be successful in lowering glycemic levels but also to improve cardio-renal outcomes in diabetic patients. Furthermore, Dapagliflozin is the first anti-diabetic drug to show cardiac and renal benefits even in those who do not have diabetes. As a result, Dapagliflozin has paved the way for a future organ protection strategy for diabetes as well as non-diabetes.

Published in	International Journal of Diabetes and Endocrinology (Volume 7, Issue 2)
DOI	10.11648/j.ijde.20220702.11
Page(s)	22-28
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Dapagliflozin, Type 2 Diabetes, SGLT2 Inhibitors, DAPA-HF, DAPA-CKD, Heart Failure, CKD

References

[1]	International Diabetes Federation (IDF) Diabetes Atlas. 10th Edition (2021). Adapted from https://diabetesatlas.org/atlas/tenth-edition/ as accessed on 18 Feb 2021.
[2]	Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12 (12): 2032-2045. doi: 10.2215/CJN.11491116.
[3]	Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58 (4): 773-795. doi: 10.2337/db09-9028.
[4]	Kalra S. Recent advances in pathophysiology of diabetes: beyond the dirty dozen. J Pak Med Assoc. 2013 Feb; 63 (2): 277-80.
[5]	Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358 (24): 2545-59. doi: 10.1056/NEJMoa0802743.
[6]	Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358 (24): 2560-72. doi: 10.1056/NEJMoa0802987.
[7]	Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360 (2): 129-39. doi: 10.1056/NEJMoa0808431.
[8]	Harris SB, Cheng AYY, Davies MJ, Gerstein HC, Green JB, Skolnik N. Person-Centered, Outcomes-Driven Treatment: A New Paradigm for Type 2 Diabetes in Primary Care. Arlington (VA): American Diabetes Association; 2020 May.
[9]	Lahiri SW. Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. Clin Diabetes. 2017; 35 (5): 321-328. doi: 10.2337/cd17-0083.
[10]	Jacob S, Krentz AJ, Deanfield J, Rydén L. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs. 2021; 81 (12): 1373-1379. doi: 10.1007/s40265-021-01554-6.
[11]	Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019; 79 (18): 2013. doi: 10.1007/s40265-019-01239-1.
[12]	D. J. Wexler. Sodium-glucose co-transporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus. UpToDate, pp. 1–29, 2020, [Online]. Available: https://www.uptodate.com/contents/sodium-glucose-co-transporter-2-inhibitors-for-the-treatment-of-hyperglycemia-in-type-2-diabetes-mellitus?source=history_widget. as accessed on 18 Feb 2022.
[13]	Singh AK, Unnikrishnan AG, Zargar AH, Kumar A, Das AK, Saboo B, et al. Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Ther. 2019; 10 (2): 393-428. doi: 10.1007/s13300-019-0562-1.
[14]	Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019; 380 (4): 347-357. doi: 10.1056/NEJMoa1812389.
[15]	Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm - 2020 Executive Summary. Endocr Pract. 2020; 26 (1): 107-139. doi: 10.4158/CS-2019-0472.
[16]	Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. American Diabetes Association Professional Practice Committee; American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45 (Supplement_1): S125-S143. doi: 10.2337/dc22-S009.
[17]	Viswanathan V, Singh KP. Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). Diabetes Technol Ther. 2019; 21 (8): 415-422. doi: 10.1089/dia.2019.0052.
[18]	McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381 (21): 1995-2008. doi: 10.1056/NEJMoa1911303.
[19]	Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383 (15): 1436-1446. doi: 10.1056/NEJMoa2024816.
[20]	FARXIGA-dapagliflozin tablet- Full Prescribing Information. Adapted from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69 as accessed on 18 Feb 2022.
[21]	Forxiga- dapagliflozin tablet- Summary of Product Characteristics. Adapted from https://www.medicines.org.uk/emc/product/7607/smpc as accessed on 18 Feb 2022.
[22]	Recommendations of the SEC (Cardiovascular & Renal). Adapted from https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendation of SEC (Cardio & renal) 07.01.2021 & 08.01.2021.pdf. as accessed on 18 Feb 2022.
[23]	ClinicalTrials.gov. Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack (DAPA-MI) Adapted from https://clinicaltrials.gov/ct2/show/NCT04564742 as accessed on 18 Feb 2022.
[24]	ClinicalTrials.gov. Efficacy and Safety of Dapagliflozin in Acute Heart Failure (DICTATE-AHF) Adapted from https://clinicaltrials.gov/ct2/show/NCT04298229 as accessed on 18 Feb 2022.
[25]	Nicholson MK, Ghazal Asswad R, Wilding JP. Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. Expert Opin Pharmacother. 2021; 22 (17): 2303-2310. doi: 10.1080/14656566.2021.1953471.

Cite This Article

Plain Text BibTeX RIS

APA Style

Manish Maladkar, Ashok Yadav, Shraddha Ghorui. (2022). Changing Era of Diabetes Management – A New Perspective for Dapagliflozin. International Journal of Diabetes and Endocrinology, 7(2), 22-28. https://doi.org/10.11648/j.ijde.20220702.11

Copy | Download

ACS Style

Manish Maladkar; Ashok Yadav; Shraddha Ghorui. Changing Era of Diabetes Management – A New Perspective for Dapagliflozin. Int. J. Diabetes Endocrinol. 2022, 7(2), 22-28. doi: 10.11648/j.ijde.20220702.11

Copy | Download

AMA Style

Manish Maladkar, Ashok Yadav, Shraddha Ghorui. Changing Era of Diabetes Management – A New Perspective for Dapagliflozin. Int J Diabetes Endocrinol. 2022;7(2):22-28. doi: 10.11648/j.ijde.20220702.11

Copy | Download

@article{10.11648/j.ijde.20220702.11,
  author = {Manish Maladkar and Ashok Yadav and Shraddha Ghorui},
  title = {Changing Era of Diabetes Management – A New Perspective for Dapagliflozin},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {7},
  number = {2},
  pages = {22-28},
  doi = {10.11648/j.ijde.20220702.11},
  url = {https://doi.org/10.11648/j.ijde.20220702.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20220702.11},
  abstract = {Type 2 Diabetes Mellitus (T2DM) treatment has progressed dramatically in recent decades. The recent major expansion of the evidence base for T2DM treatment has resulted in frequent revisions of guidelines for hyperglycemia management. When there were few pharmaceutical options, the management strategy was glucocentric or hyperglycemic control. There has been a significant change from the glucocentric era to a more patient-centered and organ-protection era evident in clinical practice guidelines of diabetes management. In addition, since the diabetes armamentarium has grown and new information has been available, the focus has shifted from hyperglycemia control to a more holistic approach, including cardiovascular and renal benefits of the drugs and safety concerns such as weight gain, hypoglycemia. The introduction of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor class of medications has had a substantial impact on diabetes management. The constant positive findings of multiple Cardiovascular Outcome Trials (CVOTs) with SGLT2 inhibitors prompted a paradigm shift: from hyperglycemia control to a patient-centered approach. As a result, SGLT2 inhibitors have been identified by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as an ideal class for a more patient-centered approach to T2DM treatment, become a driving force in diabetes care. Dapagliflozin, an SGLT2 inhibitor, has recently emerged as a glucose-lowering medication that has been found to not only be successful in lowering glycemic levels but also to improve cardio-renal outcomes in diabetic patients. Furthermore, Dapagliflozin is the first anti-diabetic drug to show cardiac and renal benefits even in those who do not have diabetes. As a result, Dapagliflozin has paved the way for a future organ protection strategy for diabetes as well as non-diabetes.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Changing Era of Diabetes Management – A New Perspective for Dapagliflozin
AU  - Manish Maladkar
AU  - Ashok Yadav
AU  - Shraddha Ghorui
Y1  - 2022/04/09
PY  - 2022
N1  - https://doi.org/10.11648/j.ijde.20220702.11
DO  - 10.11648/j.ijde.20220702.11
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 22
EP  - 28
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20220702.11
AB  - Type 2 Diabetes Mellitus (T2DM) treatment has progressed dramatically in recent decades. The recent major expansion of the evidence base for T2DM treatment has resulted in frequent revisions of guidelines for hyperglycemia management. When there were few pharmaceutical options, the management strategy was glucocentric or hyperglycemic control. There has been a significant change from the glucocentric era to a more patient-centered and organ-protection era evident in clinical practice guidelines of diabetes management. In addition, since the diabetes armamentarium has grown and new information has been available, the focus has shifted from hyperglycemia control to a more holistic approach, including cardiovascular and renal benefits of the drugs and safety concerns such as weight gain, hypoglycemia. The introduction of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor class of medications has had a substantial impact on diabetes management. The constant positive findings of multiple Cardiovascular Outcome Trials (CVOTs) with SGLT2 inhibitors prompted a paradigm shift: from hyperglycemia control to a patient-centered approach. As a result, SGLT2 inhibitors have been identified by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as an ideal class for a more patient-centered approach to T2DM treatment, become a driving force in diabetes care. Dapagliflozin, an SGLT2 inhibitor, has recently emerged as a glucose-lowering medication that has been found to not only be successful in lowering glycemic levels but also to improve cardio-renal outcomes in diabetic patients. Furthermore, Dapagliflozin is the first anti-diabetic drug to show cardiac and renal benefits even in those who do not have diabetes. As a result, Dapagliflozin has paved the way for a future organ protection strategy for diabetes as well as non-diabetes.
VL  - 7
IS  - 2
ER  -

Copy | Download

Author Information

Manish Maladkar

Scientific Department, Aristo Pharmaceuticals Private Ltd., Mumbai, India
Ashok Yadav

Scientific Department, Aristo Pharmaceuticals Private Ltd., Mumbai, India
Shraddha Ghorui

Scientific Department, Aristo Pharmaceuticals Private Ltd., Mumbai, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Manish Maladkar, Ashok Yadav, Shraddha Ghorui. (2022). Changing Era of Diabetes Management – A New Perspective for Dapagliflozin. International Journal of Diabetes and Endocrinology, 7(2), 22-28. https://doi.org/10.11648/j.ijde.20220702.11

Copy | Download

ACS Style

Manish Maladkar; Ashok Yadav; Shraddha Ghorui. Changing Era of Diabetes Management – A New Perspective for Dapagliflozin. Int. J. Diabetes Endocrinol. 2022, 7(2), 22-28. doi: 10.11648/j.ijde.20220702.11

Copy | Download

AMA Style

Manish Maladkar, Ashok Yadav, Shraddha Ghorui. Changing Era of Diabetes Management – A New Perspective for Dapagliflozin. Int J Diabetes Endocrinol. 2022;7(2):22-28. doi: 10.11648/j.ijde.20220702.11

Copy | Download

@article{10.11648/j.ijde.20220702.11,
  author = {Manish Maladkar and Ashok Yadav and Shraddha Ghorui},
  title = {Changing Era of Diabetes Management – A New Perspective for Dapagliflozin},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {7},
  number = {2},
  pages = {22-28},
  doi = {10.11648/j.ijde.20220702.11},
  url = {https://doi.org/10.11648/j.ijde.20220702.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20220702.11},
  abstract = {Type 2 Diabetes Mellitus (T2DM) treatment has progressed dramatically in recent decades. The recent major expansion of the evidence base for T2DM treatment has resulted in frequent revisions of guidelines for hyperglycemia management. When there were few pharmaceutical options, the management strategy was glucocentric or hyperglycemic control. There has been a significant change from the glucocentric era to a more patient-centered and organ-protection era evident in clinical practice guidelines of diabetes management. In addition, since the diabetes armamentarium has grown and new information has been available, the focus has shifted from hyperglycemia control to a more holistic approach, including cardiovascular and renal benefits of the drugs and safety concerns such as weight gain, hypoglycemia. The introduction of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor class of medications has had a substantial impact on diabetes management. The constant positive findings of multiple Cardiovascular Outcome Trials (CVOTs) with SGLT2 inhibitors prompted a paradigm shift: from hyperglycemia control to a patient-centered approach. As a result, SGLT2 inhibitors have been identified by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as an ideal class for a more patient-centered approach to T2DM treatment, become a driving force in diabetes care. Dapagliflozin, an SGLT2 inhibitor, has recently emerged as a glucose-lowering medication that has been found to not only be successful in lowering glycemic levels but also to improve cardio-renal outcomes in diabetic patients. Furthermore, Dapagliflozin is the first anti-diabetic drug to show cardiac and renal benefits even in those who do not have diabetes. As a result, Dapagliflozin has paved the way for a future organ protection strategy for diabetes as well as non-diabetes.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Changing Era of Diabetes Management – A New Perspective for Dapagliflozin
AU  - Manish Maladkar
AU  - Ashok Yadav
AU  - Shraddha Ghorui
Y1  - 2022/04/09
PY  - 2022
N1  - https://doi.org/10.11648/j.ijde.20220702.11
DO  - 10.11648/j.ijde.20220702.11
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 22
EP  - 28
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20220702.11
AB  - Type 2 Diabetes Mellitus (T2DM) treatment has progressed dramatically in recent decades. The recent major expansion of the evidence base for T2DM treatment has resulted in frequent revisions of guidelines for hyperglycemia management. When there were few pharmaceutical options, the management strategy was glucocentric or hyperglycemic control. There has been a significant change from the glucocentric era to a more patient-centered and organ-protection era evident in clinical practice guidelines of diabetes management. In addition, since the diabetes armamentarium has grown and new information has been available, the focus has shifted from hyperglycemia control to a more holistic approach, including cardiovascular and renal benefits of the drugs and safety concerns such as weight gain, hypoglycemia. The introduction of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor class of medications has had a substantial impact on diabetes management. The constant positive findings of multiple Cardiovascular Outcome Trials (CVOTs) with SGLT2 inhibitors prompted a paradigm shift: from hyperglycemia control to a patient-centered approach. As a result, SGLT2 inhibitors have been identified by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as an ideal class for a more patient-centered approach to T2DM treatment, become a driving force in diabetes care. Dapagliflozin, an SGLT2 inhibitor, has recently emerged as a glucose-lowering medication that has been found to not only be successful in lowering glycemic levels but also to improve cardio-renal outcomes in diabetic patients. Furthermore, Dapagliflozin is the first anti-diabetic drug to show cardiac and renal benefits even in those who do not have diabetes. As a result, Dapagliflozin has paved the way for a future organ protection strategy for diabetes as well as non-diabetes.
VL  - 7
IS  - 2
ER  -

Copy | Download